*Managed global prosecution and strategic portfolio development of blockbuster marketed and late phase (Phase II/III) therapeutic biologics across key therapeutic areas including FASENRA® (respiratory), LUMOXITI® (oncology), nirsevimab (infectious disease), tralokinumab (respiratory), and brazikumab (autoimmune).*Transformed digital IP strategy and pioneered implementation across Data Science/AI and Digital Health organizations within R&D and commercial businesses. Counsel R&D and commercial business partners to thoughtfully manage/mitigate digital IP risks while driving commercial benefit.* IP lead on several license and research collaboration agreements including outlicensing $1.3Bn asset for late stage clinical development, and in-licensing platform technologies for use in R&D (modRNA, RNAi, biologics manufacturing).*Inaugural member of Legal I&D Ambassadors to drive local and enterprise I&D initiatives within Legal and Global IP,

Subsidiary of AstraZeneca

Develop and implement patent strategy for large and complex patent portfolio relating to respiratory, inflammation, autoimmune, oncology, infectious disease, biodefense, and platform technologies. Draft and prosecute patent applications (US and ex-US), including cost-effectively managing outside counsel. Expertise in pharmaceuticals (small molecule and biologics).Actively partner with Business Development to support licensing and merger and acquisition activities by managing all aspects of intellectual property due diligence, assisting with contract negotiations and drafting, and integrating acquired IP assets.

Support a wide range of dynamic product teams from Target Identification through Proof-of-Concept, and all phases of early and late stage clinical development. Responsibilities include: identify and evaluate inventions with commercial potential; perform and evaluate landscape searches and analyses; assess risk related to freedom to operate and exclusivity; monitor and enforce confidentiality firewalls; advise on various contract issues, 271(e)(1) exemptions, and other legal matters; develop design around strategies when appropriate. Perform due diligence investigations and analyses.

U.S. patent preparation and prosecution; foreign patent prosecution; patentability, validity, and infringement opinions; strategic patent portfolio development; and patent landscape analysis.Client counseling and patent prosecution in a broad array of technology areas, including the biotechnological, pharmaceutical, and chemical industries, in a wide range of matters related to molecular biology, pharmaceuticals, nanotechnology, image processing, food science, and complex petrochemicals.

Provided pro bono counseling and assistance to individual, small business, and public policy group clients on various patent, copyright, and trademark issues. Advised government of Sierra Leone (Ministry of Trade and Industry) in its efforts to develop IP policy and draft TRIPS-compliant IP legislation, particularly defensive and positive IP protection for traditional knowledge (e.g., folklore, plant-based products and genetic resources, and biodiversity) through patents, trademarks, and copyrights.Advised independent production company on copyright issues, including public performance rights and exemptions for public broadcasting entitiesDrafted two amicus briefs submitted before the U.S. Supreme Court:• C. Lan, and G. Groisman, U.S. Supreme Court Amicus Curiae Brief for AARP in Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124 (2006).• C. Lan, S. Brairton, and N. Kim, U.S. Supreme Court Amicus Curiae Brief for Consumer Project on Technology, Electronic Frontier Foundation, and Public Knowledge in Merck KGaA v. Integra LifeSciences I, LTD., 545 U.S. 193 (2005).